Safety Reading Notes

Read safety context beside the research guide.

The OEA source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 18426507

PubMed For Dummies Article

OEA Evidence Review: the long-form source walk-through

Quick read
  • OEA currently has 14 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 18426507
  • The evidence classes most visible in the row language are insufficient (10), and mechanistic or pharmacological (4). PMID 19413995
  • The study-design language most visible in the row language is Narrative or expert review (9), Animal study (3), Cellular or in vitro study (1), and other mapped categories (1). PMID 19285259
  • The repeated topics are OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safet... (14), which tells the reader where to start opening PubMed and DOI links. PMID 30537148

Start with the research question

OEA is built from 14 source-backed evidence row(s) and 14 research source(s). The current evidence classes read as insufficient (10), and mechanistic or pharmacological (4), and the study-design language most often reads as Narrative or expert review (9), Animal study (3), Cellular or in vitro study (1), and other mapped categories (1). PMID 18426507

The row-level question is not simply whether OEA is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safet... (14). PMID 17449181

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 23567058

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 17449181

Mechanistic evidence 4 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 15770421

Limits and uncertainty 10 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 40274041

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 23464987

Where this page has the most source density

The largest bucket surfaced for this page is OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safet...: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safet...: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 18426507

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 17449181

Bucket chapters: what the literature is circling

OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safet...: insufficient

10 research sources 10 rows (1092-1105) Evidence class: insufficient

This bucket summarizes source-backed rows focused on OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safet...: insufficient. It currently draws from 10 research source(s), so the exact study type matters. PMID 18426507

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 18426507

  • Evidence row 1092

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narr... PMID 18426507

  • Evidence row 1105

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Human clinical study; outcome measure: OEA biology, receptor pharma... PMID 31132422

OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safet...: mechanistic or pharmacological

4 research sources 4 rows (1097, 1101, 1102, 1103) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safet...: mechanistic or pharmacological. It currently draws from 4 research source(s), so the exact study type matters. PMID 17449181

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 17449181

  • Evidence row 1097

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Anim... PMID 17449181

  • Evidence row 1101

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Anim... PMID 29936173

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (4 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 18426507

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 17449181

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 29936173
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 32142797
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 30702457

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 18426507

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 17449181

Source-reading checklist for OEA

  1. Open the linked PubMed or DOI record. PMID 42068417
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 31132422
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 18426507
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 19413995
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 19285259

Source Notes

OEA source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1092

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 18426507

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and nutrition.
  2. Evidence row 1093

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 19413995

    Evidence class: insufficient; Study design: Narrative or expert review. Source: N-acylethanolamines, anandamide and food intake.
  3. Evidence row 1094

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 19285259

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
  4. Evidence row 1095

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 30537148

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.
  5. Evidence row 1096

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 23567058

    Evidence class: insufficient; Study design: Narrative or expert review. Source: A fatty gut feeling.
  6. Evidence row 1097

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 17449181

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.
  7. Evidence row 1098

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 15770421

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Regulation of food intake by oleoylethanolamide.
  8. Evidence row 1099

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 40274041

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets?
  9. Evidence row 1100

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 23464987

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Brain molecules and appetite: the case of oleoylethanolamide.
  10. Evidence row 1101

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 29936173

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice.
  11. Evidence row 1102

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 32142797

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: GPR119 Is a Potent Regulator of Human Sebocyte Biology.
  12. Evidence row 1103

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 30702457

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy.
  13. Evidence row 1104

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 42068417

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides.
  14. Evidence row 1105

    OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Human clinical study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 31132422

    Evidence class: insufficient; Study design: Human clinical study. Source: Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial.